Veronica Rendo

Dr. Veronica Rendo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
OEOana M. Enache
Oana M. Enache
VRVeronica Rendo
Veronica Rendo
MAMai Abdusamad
Mai Abdusamad
DLDaniel Lam
Daniel Lam
DDDesiree Davison
Desiree Davison
UBUri Ben-David
Uri Ben-David

4 June 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
LCLouis P. Conway
Louis P. Conway
VRVeronica Rendo
Veronica Rendo
MCMário Sérgio Póvoa Correia
Mário Sérgio Póvoa Correia
IBIngvar A. Bergdahl
Ingvar A. Bergdahl
TSTobias Sjöblom
Tobias Sjöblom
Daniel GlobischDaniel Globisch
Daniel Globisch
N‐Acetyltransferases play critical roles in the deactivation and clearance of xenobiotics, including clinical drugs. NAT2 has been classified as an arylamine N‐acetyltransferase that mainly converts aromatic amines, hydroxylamines, and hydrazines. Herein, we demonstrate that the human arylamine N‐acetyltransferase NAT2 also acetylates aliphatic endogenous amines. Metabolomic analysis and chemical synthesis revealed increased intracellular concentrations of mono‐ and diacetylated spermidine in human cell lines expressing the rapid compared to the slow acetylator NAT2 phenotype. The regioselective N8‐acetylation of monoacetylated spermidine by NAT2 answers the long‐standing question of the source of diacetylspermidine. We also identified selective acetylation of structurally diverse alkylamine‐containing drugs by NAT2, which may contribute to variations in patient responses. The results demonstrate a previously unknown functionality and potential regulatory role for NAT2, and we suggest that this enzyme should be considered for re‐classification.

9 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TPTatjana Pandzic
Tatjana Pandzic
VRVeronica Rendo
Veronica Rendo
JLJinyeong Lim
Jinyeong Lim
CLChatarina Larsson
Chatarina Larsson
JLJimmy Larsson
Jimmy Larsson
TSTobias Sjöblom
Tobias Sjöblom
Somatic PRDM2 c.4467delA mutations in colorectal cancers control histone methylation and tumor growth Somatic PRDM2 c.4467delA mutations in colorectal cancers control histone methylation and tumor growth

1 April 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LMLucy Mathot
Lucy Mathot
SKSnehangshu Kundu
Snehangshu Kundu
VLViktor Ljungström
Viktor Ljungström
JSJessica Svedlund
Jessica Svedlund
LMLotte Moens
Lotte Moens
TSTobias Sjöblom
Tobias Sjöblom
The contribution of somatic mutations to metastasis of colorectal cancers is currently unknown. To find mutations involved in the colorectal cancer metastatic process, we performed deep mutational analysis of 676 genes in 107 stages II to IV primary colorectal cancer, of which half had metastasized. The mutation prevalence in the ephrin (EPH) family of tyrosine kinase receptors was 10-fold higher in primary tumors of metastatic colorectal than in nonmetastatic cases and preferentially occurred in stage III and IV tumors. Mutational analyses in situ confirmed expression of mutant EPH receptors. To enable functional studies of EPHB1 mutations, we demonstrated that DLD-1 colorectal cancer cells expressing EPHB1 form aggregates upon coculture with ephrin B1 expressing cells. When mutations in the fibronectin type III and kinase domains of EPHB1 were compared with wild-type EPHB1 in DLD-1 colorectal cancer cells, they decreased ephrin B1–induced compartmentalization. These observations provide a mechanistic link between EPHB receptor mutations and metastasis in colorectal cancer. Cancer Res; 77(7); 1730–40. ©2017 AACR.

11 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
VRVeronica Rendo
Veronica Rendo
ISIvaylo Stoimenov
Ivaylo Stoimenov
AMAndré Mateus
André Mateus
ESElin Sjöberg
Elin Sjöberg
RSRichard Svensson
Richard Svensson
TSTobias Sjöblom
Tobias Sjöblom
Cancer chemotherapy targeting frequent loss of heterozygosity events is an attractive concept, since tumor cells may lack enzymatic activities present in normal constitutional cells. To find exploitable targets, we map prevalent genetic polymorphisms to protein structures and identify 45 nsSNVs (non-synonymous small nucleotide variations) near the catalytic sites of 17 enzymes frequently lost in cancer. For proof of concept, we select the gastrointestinal drug metabolic enzyme NAT2 at 8p22, which is frequently lost in colorectal cancers and has a common variant with 10-fold reduced activity. Small molecule screening results in a cytotoxic kinase inhibitor that impairs growth of cells with slow NAT2 and decreases the growth of tumors with slow NAT2 by half as compared to those with wild-type NAT2. Most of the patient-derived CRC cells expressing slow NAT2 also show sensitivity to 6-(4-aminophenyl)-N-(3,4,5-trimethoxyphenyl)pyrazin-2-amine (APA) treatment. These findings indicate that the therapeutic index of anti-cancer drugs can be altered by bystander mutations affecting drug metabolic genes.

27 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
VRVeronica Rendo
Veronica Rendo
MSMichael Schubert
Michael Schubert
NKNicholas Khuu
Nicholas Khuu
MRMaria F. Suarez Peredo Rodriguez
Maria F. Suarez Peredo Rodriguez
DWDeclan Whyte
Declan Whyte
FFFloris Foijer
Floris Foijer
While the effect of amplification-induced oncogene expression in cancer is known, the impact of copy-number gains on “bystander” genes is less understood. We create a comprehensive map of dosage compensation in cancer by integrating expression and copy number profiles from over 8000 tumors in The Cancer Genome Atlas and cell lines from the Cancer Cell Line Encyclopedia. Additionally, we analyze 17 cancer open reading frame screens to identify genes toxic to cancer cells when overexpressed. Combining these approaches, we propose a class of ‘Amplification-Related Gain Of Sensitivity’ (ARGOS) genes located in commonly amplified regions, yet expressed at lower levels than expected by their copy number, and toxic when overexpressed. We validate RBM14 as an ARGOS gene in lung and breast cancer cells, and suggest a toxicity mechanism involving altered DNA damage response and STING signaling. We additionally observe increased patient survival in a radiation-treated cancer cohort with RBM14 amplification.